Clinical Features of Li-Fraumeni Syndrome in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Li-Fraumeni syndrome (LFS) is a hereditary disorder caused by germline mutation in <i>TP53</i>. Owing to the rarity of LFS, data on its clinical features are limited. This study aimed to evaluate the clinical characteristics and prognosis of Korean patients with LFS.Materials and Methods Patients who underwent genetic counseling and confirmed with germline <i>TP53</i> mutation in the National Cancer Center in Korea between 2011 and 2022 were retrospectively reviewed. Data on family history with pedigree, types of mutation, clinical features, and prognosis were collected.Results Fourteen patients with LFS were included in this study. The median age at diagnosis of the first tumor was 32 years. Missense and nonsense mutations were observed in 13 and one patients, respectively. The repeated mutations were p.Arg273His, p.Ala138Val, and pPro190Leu. The sister with breast cancer harbored the same mutation of p.Ala138Val. Seven patients had multiple primary cancers. Breast cancer was most frequently observed, and other types of tumor included sarcoma, thyroid cancer, pancreatic cancer, brain tumor, adrenocortical carcinoma, ovarian cancer, endometrial cancer, colon cancer, vaginal cancer, skin cancer, and leukemia. The median follow-up period was 51.5 months. Two and four patients showed local recurrence and distant metastasis, respectively. Two patients died of leukemia and pancreatic cancer 3 and 23 months after diagnosis, respectively.Conclusion This study provides information on different characteristics of patients with LFS, including types of mutation, types of cancer, and prognostic outcomes. For more appropriate management of these patients, proper genetic screening and multidisciplinary discussion are required.
Abstract
Purpose Li-Fraumeni syndrome (LFS) is a hereditary disorder caused by germline mutation in TP53. Owing to the rarity of LFS, data on its clinical features are limited. This study aimed to evaluate the clinical characteristics and prognosis of Korean patients with LFS. Materials and Methods Patients who underwent genetic counseling and confirmed with germline TP53 mutation in the National Cancer Center in Korea between 2011 and 2022 were retrospectively reviewed. Data on family history with pedigree, types of mutation, clinical features, and prognosis were collected. Results Fourteen patients with LFS were included in this study. The median age at diagnosis of the first tumor was 32 years. Missense and nonsense mutations were observed in 13 and one patients, respectively. The repeated mutations were p.Arg273His, p.Ala138Val, and pPro190Leu. The sister with breast cancer harbored the same mutation of p.Ala138Val. Seven patients had multiple primary cancers. Breast cancer was most frequently observed, and other types of tumor included sarcoma, thyroid cancer, pancreatic cancer, brain tumor, adrenocortical carcinoma, ovarian cancer, endometrial cancer, colon cancer, vaginal cancer, skin cancer, and leukemia. The median follow-up period was 51.5 months. Two and four patients showed local recurrence and distant metastasis, respectively. Two patients died of leukemia and pancreatic cancer 3 and 23 months after diagnosis, respectively. Conclusion This study provides information on different characteristics of patients with LFS, including types of mutation, types of cancer, and prognostic outcomes. For more appropriate management of these patients, proper genetic screening and multidisciplinary discussion are required.
참고문헌 (30)
- Schneider K, "GeneReviews" (1993), University of Washington
- Malkin D, "Li-fraumeni syndrome", Genes Cancer, 2, pp.47584~ (2011)
- Harris CC, "Structure and function of the p53 tumor suppres sor gene : clues for rational cancer therapeutic strategies", J Natl Cancer Inst, 88, pp.1442~1455 (1996)
- Aubrey BJ, "Tumor-suppressor functions of the TP53 pathway", Cold Spring Harb Perspect Med, 6, pp.a026062~ (2016)
- Mai PL, "Risks of first and subsequent cancers among TP53mutation carriers in the National Cancer Institute Li-Frau meni syndrome cohort", Cancer, 122, pp.3673~3681 (2016)
- Guha T, "Inherited TP53 mutations and the Li-Frau-meni syndrome", Cold Spring Harb Perspect Med, 7, pp.a026187~ (2017)
- Bouaoun L, "TP53 variations in human cancers : new les sons from the IARC TP53 Database and Genomics Data", Hum Mutat, 37, pp.865~876 (2016)
- Leroy B, "TP53 mutations in human cancer : database reassessment and prospects for the next dec ade", Hum Mutat, 35, pp.672~688 (2014)
- Park KJ, "Germline TP53mutation and clinical characteristics of Korean patients with Li-Fraumeni syndrome", Ann Lab Med, 36, pp.463~468 (2016)
- Alyami H, "Clinical features of breast cancer in South Korean patients with germline TP53 gene mutations", J Breast Cancer, 24, pp.175~182 (2021)
- Bang YJ, "The first documentation of Li-Fraumeni syndrome in Korea", J Korean Med Sci, 10, pp.205~210 (1995)
- Kim IJ, "Famil ial gastric cancers with Li-Fraumeni syndrome : a case repast", World J Gastroenterol, 11, pp.4124~4126 (2005)
- Baek YS, "Li-Fraumeni syndrome presenting as cutaneous melanoma in a child : case report and review of literature", J Eur Acad Dermatol Venereol, 33, pp.e174~e175 (2019)
- Hwang SM, "Genetic counseling can influence the course of a suspected familial cancer syndrome patient : from a case of Li-Fraumeni like syndrome with a ger mline mutation in the TP53 gene", Korean J Lab Med, 28, pp.493~497 (2008)
- Shin HJ, "Family of Li-Fraumeni syndrome with a germline mutation in the p53 gene", Clin Pediatr Hematol Oncol, 16, pp.38~42 (2009)
- Cho Y, "A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer", Ann Lab Med, 33, pp.212~216 (2013)
- Oh CS, "Osteosarcoma with adeno carcinoma of lung in Li-Fraumeni syndrome : a case report", J Korean Bone Joint Tumor Soc, 20, pp.99~103 (2014)
- Ku I, "Dermatofibrosarcoma in Li-Fraumeni syn drome with early-onset multiple primary tumors", J Dermatol, 47, pp.e333~e335 (2020)
- Hisada M, "Multi ple primary cancers in families with Li-Fraumeni syndrome", J Natl Cancer Inst, 90, pp.606~611 (1998)
- Bougeard G, "Revisiting Li-Fraumeni syndrome from TP53 mutation carriers", J Clin Oncol, 33, pp.2345~2352 (2015)
- Nichols KE, "Germ line p53 mutations predispose to a wide spectrum of early-onset cancers", Cancer Epidemiol Biomarkers Prev, 10, pp.83~87 (2001)
- Kasuga A, "Molecular features and clinical management of hereditary pancreatic cancer syndromes and familial pancre atic cancer", Int J Mol Sci, 23, pp.1205~ (2022)
- Ariffin H, "Frequent occurrence of gastric cancer in Asian kin dreds with Li-Fraumeni syndrome", Clin Genet, 88, pp.450~455 (2015)
- Acheampong T, "Incidence trends of breast cancer molecular subtypes by age and race", ethnicity in the US from 2010 to 2016, 2020, pp.3, e2013226~
- Masciari S, "Breast cancer phenotype in women with TP53germline mutations : a Li-Fraumeni syndrome consortium effort", Breast Cancer Res Treat, 133, pp.1125~1130 (2012)
- Sandoval RL, "Breast cancer phenotype associated with Li-Fraumeni syndrome : a Brazilian cohort enriched by TP53p. R337H carriers", Front Oncol, 12, pp.836937~ (2022)
- Yoon IN, "Breast cancer after radiation therapy in a patient with Li-Fraumeni syndrome : a case report", Taehan Yongsang Uihakhoe Chi, 83, pp.246~251 (2022)
- Braunstein S, "Radiotherapy-induced malignan cies : review of clinical features, pathobiology, and evolving approaches for mitigating risk", Front Oncol, 3, pp.73~ (2013)
- Le AN, "Frequency of radiation-induced malignancies post adjuvant radiotherapy for breast cancer in patients with Li Fraumeni syndrome", Breast Cancer Res Treat, 181, pp.181~188 (2020)
- Talwalkar SS, "Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome", Arch Pathol Lab Med, 134, pp.1010~1015 (2010)